NCS Healthcare Glycopyrrolate Recall Highlights Critical Impurity Control Failures for Institutional Supply
NCS Healthcare of Kentucky Inc initiated a Class II recall for 6,929 blister cards of Glycopyrrolate Tabs, USP, 1 mg, due to high out-of-specification results for individual unknown impurities. This event, terminated on February 19, 2021, signals critical quality control deficiencies impacting institutional pharmaceutical supply chains. Procurement and regulatory teams must reassess supplier qualification and product quality assurance protocols for similar drug products.
What the FDA Found: Summary of Quality Violations Leading to Recall
NCS Healthcare of Kentucky Inc initiated a Class II recall (D-0850-2020) for its Glycopyrrolate Tabs, USP, 1 mg, specifically 30-count unit dose blister cards intended for institutional use. The primary reason for this significant regulatory action was the product's failure to meet established impurity and degradation specifications. Investigations revealed high out-of-specification (OOS) results for individual unknown impurities, indicating a critical lapse in quality control and manufacturing processes. This recall, which commenced on January 28, 2020, and was terminated by the FDA on February 19, 2021, impacted 6,929 blister cards from Lot #: 8170-9004, with an expiration date of January 2020. The distribution pattern was nationwide across the USA, highlighting a broad exposure for institutional buyers. For procurement directors and regulatory affairs heads, this event underscores the imperative of robust supplier auditing, particularly concerning impurity profiles and degradation pathways for active pharmaceutical ingredients (APIs) and finished drug products. The presence of unknown impurities at OOS levels signals potential risks to patient safety and necessitates immediate corrective and preventive actions (CAPA) by the manufacturer and distributor.
Operational Impact: Facility and Product Scope for Glycopyrrolate Supply
The recall directly involves NCS Healthcare of Kentucky Inc, located at 120 Carroll Knicely Dr, Glasgow, KY 42141-7224, United States. The affected product, Glycopyrrolate Tabs, USP, 1 mg, is specifically packaged as a 30-count unit dose blister card, identified by NDC 0615-8170-39. This formulation is explicitly designated "FOR INSTITUTIONAL USE ONLY" and is available by prescription (Rx Only), with packaging handled by Vangard, also based in Glasgow, KY. For supply chain VPs and business development executives, this specificity means that the immediate impact is concentrated within institutional purchasing channels, such as hospitals, long-term care facilities, and government healthcare providers. The recall of 6,929 blister cards, while not a massive volume in the broader market, represents a significant disruption for the specific institutional clients reliant on this particular packaging and dosage. Companies sourcing Glycopyrrolate or similar anticholinergic medications for institutional distribution must verify the provenance and quality assurance records of their suppliers, especially those involved in secondary packaging or distribution, to ensure compliance with impurity specifications and overall product integrity.
Regulatory Risk and Supply Chain Due Diligence Post-Recall
While this event was classified as a voluntary, firm-initiated Class II recall, the underlying issue of "Failed Impurities/Degradation Specification" represents a significant regulatory risk that often precedes or accompanies more severe FDA actions, including Warning Letters. For regulatory affairs heads, the termination of the recall on February 19, 2021, indicates that the immediate product removal and containment were completed. However, the FDA's scrutiny extends beyond the recall's termination to the root cause analysis and the effectiveness of implemented CAPAs. Persistent or recurring quality control issues, particularly those involving unknown impurities, can trigger enhanced surveillance, facility inspections, and potentially lead to future enforcement actions against NCS Healthcare of Kentucky Inc or its packaging partner, Vangard. Procurement directors must conduct thorough due diligence, including on-site audits and review of quality management systems, for any supplier implicated in such quality failures. This proactive approach is crucial to mitigate future supply chain disruptions, protect patient safety, and maintain regulatory compliance across their pharmaceutical portfolios, especially for critical institutional-use medications like Glycopyrrolate.